Q3 2024 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2024-11-14 · accession 0001937964-24-000006
$366.9M
Reported value
45
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670100205 | NVO | NOVO-NORDISK A S | $88.3M | 24.1% | 741,743 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $82.0M | 22.4% | 92,593 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $33.7M | 9.20% | 532,879 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $15.8M | 4.32% | 216,519 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $14.9M | 4.05% | 190,752 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $13.9M | 3.78% | 274,424 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $13.3M | 3.62% | 15,000 | PUT | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $9.6M | 2.62% | 35,000 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $8.8M | 2.40% | 18,900 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $8.7M | 2.38% | 76,255 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $8.2M | 2.24% | 15,138 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $7.9M | 2.15% | 87,848 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $5.6M | 1.53% | 124,440 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $5.2M | 1.41% | 45,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.3M | 1.19% | 95,885 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $4.3M | 1.17% | 119,488 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $4.3M | 1.17% | 148,590 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $4.0M | 1.09% | 80,171 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $3.9M | 1.05% | 52,939 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $2.6M | 0.70% | 75,300 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $2.3M | 0.64% | 45,765 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $2.0M | 0.54% | 62,992 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.7M | 0.47% | 421,359 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $1.7M | 0.47% | 53,930 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $1.6M | 0.43% | 15,437 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.6M | 0.43% | 40,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $1.3M | 0.35% | 80,380 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $1.2M | 0.34% | 156,300 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $1.2M | 0.34% | 6,305 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $1.2M | 0.33% | 30,479 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $1.2M | 0.32% | 20,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $1.1M | 0.30% | 57,178 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.1M | 0.30% | 7,440 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $1.0M | 0.28% | 172,226 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $977,862 | 0.27% | 47,400 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $954,014 | 0.26% | 52,476 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $929,063 | 0.25% | 48,263 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $901,131 | 0.25% | 54,285 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $900,857 | 0.25% | 193,317 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $660,442 | 0.18% | 13,440 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $592,710 | 0.16% | 90,490 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $459,052 | 0.13% | 93,114 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $330,427 | 0.09% | 1,557 | Common | SOLE |
| 86627T108 | SMMT | SUMMIT THERAPEUTICS INC | $317,813 | 0.09% | 14,512 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $209,937 | 0.06% | 4,705 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.